COPEXIS S.A. is a quality-driven consultancy firm with expertise in:
· Drug development (manufacturing, safety/toxicology, clinical, regulatory)
· Drug regulatory services (CH/EU)
· Corporate development and management
Understanding the client’s issue or challenge is the starting point of all what we do. We listen, brainstorm and then recommend and support the implementation of the strategic solution where and when required.
Copexis offers drug development and strategic advice across and within all our areas of expertise of more than 30 years in the pharmaceutical industry and more than 40 products (proteins, peptides, small molecules, cell and gene therapy).
Copexis not only provides advice but also supports “hands-on” the implementation of the manufacturing, toxicology, clinical and regulatory programs.
Our track record includes the development support of marketed therapeutic drugs with yearly sales up to 1 billion € and therapeutic drugs licensed or optioned for up to 1’2 billion €.
Our core focus is early stage drug development from the development candidate up to clinical phase II studies. Given our past expertise, we also support later stages programs including phase III and registration in Europe and Switzerland.
Copexis S.A.
59 chemin des Brûlées
CH-1093 Lutry/Lausanne
Switzerland
tel: +41 79 771 271 9
dc@copexis.com